|
Indian Pediatr 2020;57:
963-964 |
 |
A Preliminary Report of COVID-19 in Children in India
|
Sourav Banerjee,1 Aritra Guha,2
Avishikta Das,2 Mousami Nandi1 and Rakesh Mondal1*
Departments of Pediatrics, 1Medical College
Kolkata, Kolkata; and 2NB Medical College,
Darjeeling; West Bengal, India.
Email:
[email protected]
Published online: July 28, 2020;
PII: S097475591600217
|
We describe the profile of COVID-19
in children from India in this multicentre observational study from
tertiary care hospitals in West Bengal. Data of children up to 12 years
presenting with positive results on SARS-CoV-2 RT-PCR test were
included. The median (IQR) age of the 41 patients included was 1
(0.42-5.0) year. Eleven (26.8%) patients, including 6 neonates, never
showed any symptoms. Fever was seen in only 9 patients (21%), and co-morbities
were found in 61% of patients. There was one death.
Keywords: Co-morbidities, Course,
Management, Outcome.
|
T he clinical profile of Corona
Virus Disease 2019 (COVID-19) infection in children is variable, and
information from developing countries is not readily available, except
for China [1]. We report a series of pediatric cases of COVID-19 from
eastern India.
We collected data of children younger than 12 years
admitted in tertiary care institutes, including COVID designated
hospitals, of West Bengal. The children were included after obtaining
parental consent, if they had a positive RT-PCR test report for
SARS-CoV-2. The study was conducted from March, 2020 to June, 2020.
Ethical permission was sought from the institutional ethics committee.
RT-PCR for SARS-CoV-2 in an Indian Council of Medical
Research (ICMR) approved medical laboratory, data regarding clinical
details, exposure history, hospital course and outcome were collected in
pre-designed proforma. The records were entered and updated by pediatric
residents and subsequently reviewed by a senior pediatric faculty of the
institute. Data were compiled in Microsoft Excel spreadsheet and
summarized.
We studied 41 patients (24 boys) with the median
(IQR) age of 1 (0.42-5.0) year. Majority of the cases, 40 (97.6%) were
successfully discharged, with one death. We had 6 neonates with
COVID-19, all of whom were born to SARS-COV-2 positive mothers and were
asymptomatic. Of the rest, five patients never showed any symptoms
throughout the period of isolation, while 14 (34%) were mildly
symptomatic in the form of common cold and rhinorrhea. Fever, which is
perceived to be a major presenting feature of COVID-19, was seen only in
9 patients (21%).
Two cases had multi-system involvement in the form of
an atypical Kawasaki disease-like presentation. Almost 61% of the cases
had associated co-morbidities (Table I). Eleven (26.8%)
patients needed no active management, 34% mildly symptomatic children
needed nasal drops and anti-histaminics, 24.4% required oxygen
inhalation, 4.9% were put on high flow nasal canula (HFNC) and 4.9%
needed mechanical ventilation. Six (15%) patients required intensive
care. Of the study population, only 63.4% had a positive contact
history. One child died in this series due to type II respiratory
failure with septic shock in a case of post adenoviral bronchiolitis
obliterans and hypoxic brain injury.
Table I Characteristics of Children With COVID-19 (N=41)
Characteristics |
No. (%) |
Age group |
|
<28 d |
6 (14.6) |
28 d -<1 y |
12 (29.3) |
1-5 y |
15 (36.6) |
6-10 y |
6 (14.6) |
>10 y |
2 (4.9) |
Symptoms* |
|
Asymptomatic |
11(26.8) |
Mildly symptomatic
|
14 (34.1) |
Respiratory distress |
13 (31.7) |
Fever |
9 (21.0) |
Cough
|
5 (12.1) |
Diarrhea |
3 (7.3) |
Rashes |
2 (4.9) |
Co-morbidity |
25 (60.9) |
Malignancy |
8 (19.5) |
Hematological disorders
|
5 (2.2) |
Congenital heart disease |
4 (9.7) |
Neurological abnormalities
|
4 (9.7) |
Chronic lung disease |
2 (4.9) |
Multiple congenital anomalies |
2 (4.9) |
Respiratory support |
|
Oxygen
|
10 (24.4) |
High flow nasal cannula
|
2 (4.9) |
Ventilation
|
2 (4.9) |
*Shock, convulsions and sepsis like illness were present in
one child each. |
Our study found that the clinical course of COVID-19
in children appeared to be less severe than that reported in adults,
which is consistent with other reports published on COVID-19 in
children. We also found that co-morbidities were more prevalent (61%) in
the 41 children hospitalized with COVID-19 [2]. Comorbidities among
children with COVID-19 were reported in all patients from China [3] but
in 83% of those in US and Canadian intensive care units [4].
Some studies [5] have raised concerns about the
appearance of a novel severe Kawasaki-like disease in children in
association with SARS-CoV-2 infection [6]. Our study also had two such
cases with multi-system involvement in the form of an atypical Kawasaki
- like presentation, similar to previous Indian reports [7].
In a recent meta-analysis, Meena, et al. [8]
analyzed data from 27 different studies (4857 patients). They showed
that even among the symptomatic COVID-19 cases, severe manifestations
are fewer in children. They found that fever and respiratory symptoms
are most common, although many children had gastrointestinal
manifestations [8].
The study has its share of limitations of small
sample size and lack of long term follow up of co-morbidities after
discharge. In spite of these shortcomings, this study provides
preliminary data on characteristics and outcomes of COVID-19 in children
from India.
Contributors: SB: primary investigator, data
collection, making draft; AG: making draft, literature search,
interpretation, statistical help; AD: data collection, draft, Literature
search; MN: technical inputs, data collection, study conception, review
draft; RM: conception of study, reviewing draft, Study design, and
literature search. All authors approved the final manuscript.
Funding: None; Competing interest: None
stated.
REFERENCES
1. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al.
A case series of children with 2019 novel coronavirus infection:
Clinical and epidemiological features. Clin Infect Dis. 2020:ciaa198. [Epub
Ahead of print 2020 Fen 28]
2. Garg S, Kim L, Whitaker M, Halloran A, Cummings C,
Holstein R, et al; US Centers for disease control and prevention.
Hospitalization rates and characteristics of patients hospitalized with
laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states,
March 1-30, 2020. Available from:
https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm. Accessed June
30, 2020.
3. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ,
Ross CE, McKiernan CA, et al. Characteristics and outcomes of
children with coronavirus disease 2019 (COVID-19) infection admitted to
US and Canadian pediatric intensive care units. JAMA Pediatr. 2020;10
[published online ahead of print, 2020 May 11]
4. Lu X, Zhang L, Du H. SARS-CoV-2 infection in
children. N Engl J Med. 2020;23;382;17.
5. Verdoni L, Mazza A, Gervasoni A, Martelli L,
Ruggeri M, Ciuffreda M, et al. An outbreak of severe
Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2
epidemic: an observational cohort study. Lancet. 2020. Available from
https://doi.org/10.1016/S0140-6736(20) 31103-X. Accessed June 30,
2020.
6. Viner RM, Whittaker E. Kawasaki-like disease:
Emerging complication during the COVID-19 pandemic. Lancet.
2020;395:1741-3.
7. Acharyya BC, Acharyya S, Das D. Novel coronavirus,
mimicking Kawasaki disease in an infant. Indian Pediatr.
2020;S097475591600184 [E-pub ahead of print].
8. Meena J, Yadav J, Saini L, Yadav A, Kumar J.
Clinical features and outcome of SARS-CoV-2 infection in children: A
systematic review and meta-analysis. Indian Pediatr.
2020;S097475591600203 [E-pub ahead of print].
|
|
 |
|